BioSpace News Archive

The acquisition of Uniphy Health extends the suite of solutions for the Harris Healthcare group, a member of the HIMSS Informatics 100.

SentiAR, a medical device startup transforming the cardiac ablation procedures, today announced that industry expert Berk Tas has joined the company as CEO and president.

The Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization funding and accelerating prostate cancer research, announced today that the newly revised 2019 Prostate Cancer Patient Guide is available for free download on pcf.org.

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of aldoxorubicin intravenously, intra-arterially or intramuscularly for the treatment of brain cancer, which patent was exclusively licensed by CytRx to NantCell, Inc. in July 2017

Repro Med Systems, Inc. dba RMS Medical Products (OTCQX:REPR) (“RMS Medical”) today announced that R. John Fletcher has been appointed as an independent member of RMS Medical’s Board of Directors.

BioNTech SE announced the acquisition of antibody assets and infrastructure from San Diego-based MabVax Therapeutics Holding, Inc., a clinical-stage oncology drug development company.

Horizon Therapeutics plc announced its first-quarter 2019 financial results and increased its full-year 2019 net sales and adjusted EBITDA guidance.

OneDigital Health and Benefits, the nation’s largest company focused solely on employee benefits and human resources, today announced a national preferred partnership with One Drop, a leader in healthy lifestyle and condition management programs for employers.

MediLynx Cardiac Monitoring, LLC today announced new research connecting short episodes of Atrial Fibrillation called micro-AF (4 beats <29) with the presentation of clinical AF (>30 seconds).

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the Bank of America Merrill Lynch Health Care Conference, taking place May 15-17 in Las Vegas, NV.